Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Heart Failure

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,476 result(s) found for: Heart Failure. Displaying page 5 of 74.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-003510-16 Sponsor Protocol Number: EFC15156 Start Date*: 2018-05-07
    Sponsor Name:Lexicon Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabet...
    Medical condition: Cardiovascular diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) ES (Prematurely Ended) LV (Completed) LT (Completed) GB (Completed) BE (Completed) DK (Prematurely Ended) FR (Completed) AT (Completed) CZ (Prematurely Ended) DE (Completed) SK (Completed) HU (Completed) FI (Completed) PT (Completed) GR (Completed) PL (Completed) IE (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2022-004186-21 Sponsor Protocol Number: VICTORID_01 Start Date*: 2023-09-14
    Sponsor Name:Dipartimento di Medicina-DIMED, università di Padova
    Full Title: Beneficial effects of vitamin D combined with oral iron supplementation in patients with chronic heart failure and iron deficiency (VICTORID-HF TRIAL)
    Medical condition: Chronic heart failure; iron deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019284 Heart failure, congestive LLT
    20.0 10007541 - Cardiac disorders 10007558 Cardiac failure chronic PT
    20.1 10007541 - Cardiac disorders 10064081 Heart failure NYHA class III LLT
    20.1 10007541 - Cardiac disorders 10064080 Heart failure NYHA class II LLT
    24.0 100000004861 10060496 Hyposideremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000805-27 Sponsor Protocol Number: MEIN/10/Ran-Did/001 Start Date*: 2012-10-23
    Sponsor Name:Menarini International Operations Luxembourg S.A., Avenue de la Gare, 1611 Luxembourg, Luxembourg
    Full Title: Effect of Ranolazine in Heart Failure Patients with Preserved Ejection Fraction
    Medical condition: Heart failure patients with preserved ejection fraction (HFpEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019280 Heart failures HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000595-33 Sponsor Protocol Number: 2011-01-01REPEAT Start Date*: 2013-04-25
    Sponsor Name:Goethe University Frankfurt
    Full Title: Randomized controlled trial to compare the effects of single versus repeated intracoronary application of autologous bone marrow-derived mononuclear cells on total and SHFM-predicted mortality in p...
    Medical condition: Chronic post-infarction heart failure due to an at least 3 months old myocardial infarction, treated with optimal medication according to the evidence-based guidelines, in NYHA stadium II-III; and ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001809-50 Sponsor Protocol Number: C3651011 Start Date*: 2023-01-27
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 4-ARM STUDY TO INVESTIGATE SYMPTOMS, FUNCTION, HEALTH-RELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEG...
    Medical condition: Heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019280 Heart failures HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004592-23 Sponsor Protocol Number: DLIFE Start Date*: 2015-03-12
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Phase IV randomized, double blind, placebo-controlled study: role of hypovitaminosis D in heart failure and possible advantages of cholecalciferol (Vit D) administration
    Medical condition: HEART FAILURE
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10011949 Decompensation cardiac LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006718-13 Sponsor Protocol Number: R0452 Start Date*: 2007-10-11
    Sponsor Name:Hull and East Yorkshire NHS Trust
    Full Title: Opioids in the management of breathlessness in chronic heart failure
    Medical condition: Patients known to the Academic Unit of Cardiology that have symptomatic chronic heart failure (New York Heart Association grading 3-4) despite maximal medical treatment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003146-75 Sponsor Protocol Number: BETA3_LVH Start Date*: 2016-03-14
    Sponsor Name:Université catholique de Louvain (UCL)
    Full Title: A multi-centre randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on the progression of left ventricular mass and diastolic function in patients with struct...
    Medical condition: Structural heart disease at high risk for progressive hypertrophic cardiac remodeling at risk of developing HFpEF (heart failure with preserved ejection fraction).
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004849 10019290 Heart insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PT (Completed) GR (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003719-37 Sponsor Protocol Number: GN15CA580 Start Date*: 2017-07-25
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: StUdies of empaGliflozin and its cArdiovascular, Renal and metabolic effects in patients with Diabetes Mellitus (or prediabetes) and Heart Failure (SUGAR-DM-HF)
    Medical condition: Chronic heart failure with left ventricular systolic dysfunction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-007518-13 Sponsor Protocol Number: A10-290 Start Date*: 2007-12-20
    Sponsor Name:University Medical Centre Ljubljana
    Full Title: THE EFFECTS OF LEVOSIMENDAN ON ARTERIALL STIFFNESS IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE
    Medical condition: advanced chronic heart failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000486-37 Sponsor Protocol Number: CHF201701 Start Date*: 2019-03-27
    Sponsor Name:Heart Initiative
    Full Title: STRONG-HF: Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP testing, of Heart Failure therapies
    Medical condition: Acute Heart Failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003858-81 Sponsor Protocol Number: 12-025 Start Date*: 2013-07-15
    Sponsor Name:RWTH Aachen, Medizinische Fakultät
    Full Title: Effect of Linagliptin therapy on myocardial diastolic function in patients with type 2 diabetes mellitus
    Medical condition: Patients with type 2 diabetes mellitus and diastolic dysfunction
    Disease: Version SOC Term Classification Code Term Level
    17.0 10007541 - Cardiac disorders 10019280 Heart failures HLGT
    17.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003688-37 Sponsor Protocol Number: KKS-243 Start Date*: 2018-07-06
    Sponsor Name:Philipps-Universität Marburg
    Full Title: Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension (PASSION), A randomized, placebo-controll...
    Medical condition: Combined post- and pre-capillary pulmonary hypertension and heart failure with preserved ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077732 Pulmonary hypertension WHO functional class II LLT
    20.0 100000004849 10024106 Left heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000376-28 Sponsor Protocol Number: 1245.148 Start Date*: 2018-01-30
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: A randomised, double-blind, placebo-controlled, mechanistic cardiac magnetic resonance study to investigate the effects of empagliflozin treatment on cardiac physiology and metabolism in patients w...
    Medical condition: Chronic heart failure with reduced (HFrEF) and preserved ejection fraction (HFpEF) diagnosed at least 3 months prior to informed consent.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000771-24 Sponsor Protocol Number: CXL-1427-02 Start Date*: 2014-12-22
    Sponsor Name:Cardioxyl Pharmaceuticals, Inc.
    Full Title: A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6-Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients with Systolic Heart Failure
    Medical condition: Heart failure with reduced ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004849 10024106 Left heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002605-31 Sponsor Protocol Number: Aldo-DHF Start Date*: 2007-02-01
    Sponsor Name:Georg-August-Universität Göttingen
    Full Title: ALDOSTERONE RECEPTOR BLOCKADE IN DIASTOLIC HEART FAILURE A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and dia...
    Medical condition: Diastolic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002946-19 Sponsor Protocol Number: 1245-0204 Start Date*: 2020-01-15
    Sponsor Name:Boehringer Ingelheim
    Full Title: A multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, ini...
    Medical condition: Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) BE (Completed) DE (Completed) DK (Completed) ES (Completed) HU (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010236-18 Sponsor Protocol Number: CSPP100A2368 Start Date*: 2009-05-28
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo para evaluar la eficacia y seguridad a 6 meses de la terapia de aliskiren, además de la terapia estánda...
    Medical condition: Insuficiencia Cardiaca aguda descompensada
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) CZ (Completed) BE (Completed) IT (Completed) SK (Completed) PL (Completed) HU (Completed) SE (Completed) FI (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003902-29 Sponsor Protocol Number: EASI-Child Start Date*: 2020-04-30
    Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
    Full Title: Early Administration of Ivabradine in Children with Heart Failure.
    Medical condition: Acute hearth failure in dilated cardiomyopathy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002511-26 Sponsor Protocol Number: 08062019 Start Date*: 2019-12-20
    Sponsor Name:Rigshospitalet
    Full Title: Repeated Injection Therapy of Allogeneic Stem Cells in Ischemic No-option Patients - A Multi-Centre Study (SCIENCE REPEAT)
    Medical condition: Ischemic heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019285 Heart failure, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 27 22:01:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA